Story
REGENXBIO Shares Fall 12% on Planned $100 Million Stock Offering
Shares of REGENXBIO Inc. (NASDAQ: RGNX) plunged 12% in after-hours trading Thursday following the gene therapy company's announcement of a planned $100 million public stock offering.
Details of the Offering
REGENXBIO stated its intention to offer and sell the common stock in an underwritten public offering, according to a company statement. The completion, timing, and terms of the offering are subject to market and other conditions.
The company also plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares sold in the offering. Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho are serving as the joint book-running managers for the deal.
AdMarket Impact and Dilution Concerns
The sharp decline in the company's stock price reflects a typical market reaction to secondary offerings. When a company issues new shares, it increases the total number of shares outstanding, which dilutes the ownership percentage of existing shareholders.
This potential for dilution often puts immediate downward pressure on a stock's price, as investors anticipate their stake in the company will be reduced. REGENXBIO noted in its announcement that there is no assurance as to whether or when the offering may be completed.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.